Bravida Medical is proud to recognize the clinicians and researchers whose work was featured through poster presentations and an oral presentation at the 2026 Annual Meeting of the International ...
Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes ...
Phase 3 EPIDYS MRI data quantify givinostat’s potential to preserve functional muscle tissue and reduce fat infiltration in ...
“As part of the pivotal development program for bentracimab, which also includes the Phase 3 REVERSE-IT trial, the Phase 2b trial was designed to help answer important safety and efficacy questions ...
Zentalis Pharmaceuticals, Inc. announced that an abstract has been accepted for a poster presentation at the 2025 American Society of Clinical Oncology Annual Meeting, scheduled for May 30 to June 3 ...
The CASPAR classification criteria for psoriatic arthritis (PsA) identify any one of these as a necessary indication of inflammatory articular disease before the other components of the criteria may ...
HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today ...
MILAN, April 23, 2026 (GLOBE NEWSWIRE)-- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company pioneering next-generation gene therapies for inherited retinal diseases (IRDs) has today ...
MALVERN, PA & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results